This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Pompe disease / Glycogen storage disease type II / Acid maltase deficiency폼페병

Contents and key points
ItemDetails
A. Classification codesICD-10: E74.0 (glycogen storage disease) | Special Copayment Reduction: V117 (rare disease)
B. SynonymsPompe disease, glycogen storage disease type II (GSD type II), acid maltase deficiency, GAA deficiency (lysosomal alpha-glucosidase deficiency), lysosomal glycogen storage disease
C. Adult onsetLikelihood of first onset in adulthood: high — the late-onset form (late-onset Pompe disease, LOPD) remains asymptomatic until up to several decades of age and first presents with proximal muscle weakness, respiratory failure, and weakness of the paraspinal (erector spinae) muscles. Diagnosis in the 20s~60s is common, and many cases are diagnosed after being misdiagnosed for years as adult myopathy or unclassified respiratory failure.
1. History1932 first description by Pompe → 1963 Hers established the theory of lysosomal enzyme deficiency → 1990s cloning of the GAA gene → 2006 FDA approval of alglucosidase alfa (Myozyme) → 2021 approval of avalglucosidase alfa (Nexviazyme) → 2024 cipaglucosidase + miglustat combination therapy → gene therapy in clinical trials.
2. CausesPathogenic variants in the GAA gene (17q25.3) → deficiency of lysosomal acid alpha-glucosidase → glycogen accumulation within lysosomes. Autosomal recessive inheritance. Infantile form: GAA activity less than 1%. Late-onset form: residual GAA activity 1~30%.
3. GeneticsGAA: 17q25.3, 20 exons. Infantile form: loss-of-function variants such as c.-32-13T>G (del exon 18, splicing) or p.Arg854Stop. Late-onset form: c.-32-13T>G found in about 70% of Western late-onset cases (one allele). Variants frequent in Koreans: c.2238G>C (p.Trp746Cys), c.1822C>T, etc. CRIM status (cross-reactive immunological material) is important for ERT response and inhibitor formation.
4. General epidemiologyOverall prevalence about 1/40,000~1/57,000. Infantile form (IOPD): about 1/100,000. Late-onset form (LOPD): about 1/57,000. Infantile form frequent among African Americans (c.2560C>T). GAA IVS1 variant frequent in Taiwan and China. In Asia, including Korea, the proportion of LOPD is relatively high compared with the West.
5. PathophysiologyGAA deficiency → inability to break down glycogen within lysosomes → lysosomal swelling and rupture → cell damage (muscle, myocardium, respiratory muscles). Glycogen in non-lysosomal pathways also accumulates. Impaired autophagy worsens muscle fiber damage. Myocardium, skeletal muscle, and respiratory muscles are the main targets.
6. SymptomsInfantile form: cardiomegaly and heart failure (hypertrophic cardiomyopathy), generalized hypotonia (floppy infant), feeding difficulties, respiratory failure. Late-onset form: progressive proximal limb muscle weakness, respiratory muscle weakness (nocturnal hypoventilation, orthopnea), weakness of the paraspinal (erector spinae) muscles (spinal hyperextension or lordosis).
7. SignsInfantile form: cardiomegaly (chest X-ray, echocardiography), generalized hypotonia, markedly elevated CK, ECG abnormalities (shortened PR interval, QRS prolongation). Late-onset form: proximal muscle weakness, waddling gait, difficulty rising from the prone position, decreased FVC, nocturnal oxygen desaturation.
8. ScreeningNewborn screening: measurement of GAA enzyme activity on dried blood spots (DBS) (fluorometric and digital microfluidic methods). Performed in many Asian countries including Korea, Taiwan, and Japan. Family history-based genetic testing. When the late-onset form is suspected, sequential testing with CK + DBS GAA activity + GAA gene analysis.
9. DiagnosisMeasurement of GAA enzyme activity in dried blood spots or leukocytes (confirmation). GAA gene analysis (confirmation of variants on both alleles). CRIM status assessment (measurement of anti-GAA antibodies). Electromyography and muscle biopsy (supportive). Pulmonary function tests (FVC, MIP, MEP). 6-minute walk test, GSGC scale.
10. TreatmentEnzyme replacement therapy (ERT): alglucosidase alfa (Myozyme/Lumizyme, 20 mg/kg every other week), avalglucosidase alfa (Nexviazyme, 40 mg/kg every other week). Chaperone combination: miglustat (improves ERT uptake). CRIM-negative infantile form: immune tolerance induction before ERT. Respiratory support: NIV/CPAP/BiPAP. Rehabilitative physical therapy. Gene therapy in clinical trials.
11. PrognosisInfantile form before ERT: nearly all died of cardiopulmonary failure within the first year of life. Infantile form after ERT: survival greatly prolonged, but ventilator dependence and muscle weakness persist. CRIM status is a major determinant of prognosis. Late-onset form: progression can be delayed with ERT; pulmonary function is the main determinant of prognosis.
12. PreventionEarly initiation of ERT through newborn screening (minimizing cardiomyopathy and muscle damage). Immune tolerance protocols for CRIM-negative patients. Genetic counseling and prenatal diagnosis. Regular monitoring of respiratory function. Infection prevention (pneumococcal and influenza vaccines).
13. Referencesvan der Ploeg AT et al. N Engl J Med 2010 and 9 others

1. History

The history of Pompe disease began in 1932 when the Dutch pathologist Johannes Cassianus Pompe reported, at the autopsy of a girl who died of heart failure at just 7 months of age, findings of excessive glycogen accumulation throughout the myocardium, skeletal muscle, and liver. Pompe described this disease as 'idiopathic hypertrophy of the heart', and could not identify the mechanism from the case description alone.

The mechanism was elucidated in the 1950s~60s. In 1963, the Belgian biochemist Henri-Gérit Hers discovered that acid alpha-glucosidase (GAA) was deficient in the liver tissue of patients with Pompe disease. Based on this discovery, Hers established the concept of 'lysosomal storage disease', in which a lysosomal enzyme deficiency leads to intracellular accumulation of a specific substrate, and this became the cornerstone of modern lysosomal biology. Pompe disease was confirmed as the first glycogen storage disease whose mechanism was elucidated and the first example of a disease caused by lysosomal enzyme deficiency.

Genetic research progressed from 1974 to the 1990s. In 1974, measurement of GAA enzyme activity became possible in fibroblasts and amniotic fluid cells, enabling prenatal diagnosis. In the 1990s, the GAA gene (17q25.3) was cloned, and various gene variants explaining the clinical differences between the infantile and late-onset forms were identified. In particular, an important molecular epidemiological finding is that the c.-32-13T>G (IVS1) splicing variant is found on one allele in about 70% of Western late-onset patients.

The innovation in treatment was the development of enzyme replacement therapy (ERT). In the late 1990s, the research team of Arnold van der Ploeg and Ans van der Ploeg at Erasmus University in the Netherlands administered recombinant human GAA (rhGAA) to patients with infantile Pompe disease and demonstrated that cardiomegaly decreased dramatically and survival was prolonged. In 2006, the FDA approved alglucosidase alfa (Myozyme) as a treatment for infantile Pompe disease, which became a historic turning point in the treatment of Pompe disease. In 2010, in a phase 3 clinical trial in late-onset Pompe disease (the LOTS study), ERT showed significant effects in improving 6-minute walk distance and stabilizing pulmonary function.

In 2021, the FDA approved the second-generation ERT avalglucosidase alfa (Nexviazyme). This product is a high-M6P-content rhGAA with improved mannose-6-phosphate (M6P) receptor targeting; its efficiency of lysosomal targeting in muscle cells is improved over existing alglucosidase alfa, showing better improvement in motor and respiratory function in the late-onset form (COMET and VELOCITY studies). In 2024, cipaglucosidase alfa + miglustat combination therapy was approved, further expanding treatment options. GAA gene therapy (AAV-based or mRNA-based) is showing promising results at the clinical trial stage, and phase 1/2 results from trials entered from the mid-2020s are drawing attention.

In terms of newborn screening, Taiwan introduced GAA enzyme activity testing into national newborn screening in 2005 as the first in the world, and since then Pompe disease newborn screening has been implemented or introduced in many countries including the United States, Japan, Korea, Austria, and Italy. It is established that early initiation of ERT through newborn screening greatly reduces the severity of cardiomyopathy and respiratory failure in the infantile form.


2. Causes

Pompe disease (GSD type II) is a lysosomal storage disease caused by deficiency of lysosomal acid alpha-glucosidase (GAA; EC 3.2.1.20) due to pathogenic variants in the GAA gene. GAA is responsible for hydrolyzing the alpha-1,4 and alpha-1,6 glucosidic bonds of glycogen within lysosomes to release glucose. When this enzyme is deficient, glycogen within lysosomes cannot be broken down and accumulates, so the lysosomes swell and eventually rupture, damaging the cell.

The GAA gene is located on chromosome 17q25.3, spans 28 kb in total, and consists of 20 exons. The translation product is a precursor protein of 952 amino acids, which undergoes glycosylation and phosphorylation in the endoplasmic reticulum, moves to the lysosome, and then forms mature GAA through proteolytic processing. Mature GAA exists in two active forms of 76 kDa and 70 kDa.

Correlation between clinical form and genotype: when GAA activity is less than 1% of normal, infantile-onset Pompe disease (IOPD) develops, with hypertrophic cardiomyopathy and generalized hypotonia appearing rapidly within the first few months of life. When 1~30% of GAA activity remains, the late-onset form (LOPD) appears, with muscle weakness and respiratory failure manifesting progressively at various times from infancy to adulthood. In the infantile form, loss-of-function variants (nonsense, frameshift, splicing) are often present on both alleles. In the late-onset form, a compound heterozygous pattern is very common in Western patients, with c.-32-13T>G (IVS1 splicing variant, exon 2 skipping → the remaining about 10~15% normal splicing product maintains a small amount of residual GAA activity) on one allele and various missense variants on the other allele.

CRIM (Cross-Reactive Immunological Material) status: a concept decisive for ERT response and inhibitor formation. CRIM positive (CRIM+) is when some residual GAA protein is produced, so immune tolerance is maintained during ERT and anti-GAA antibody formation is low. CRIM negative (CRIM−) is when no GAA protein is produced at all (mainly homozygous or compound heterozygous for nonsense or frameshift variants); on ERT administration, GAA is recognized as a foreign protein and high sustained antibody titers (HSAT) of anti-GAA antibodies form, which can completely neutralize the effect of ERT. CRIM-negative patients must undergo an immune tolerance induction (ITI) protocol (combination of methotrexate, rituximab, and intravenous immunoglobulin) before starting ERT.

The mode of inheritance is autosomal recessive; when each parent is an asymptomatic carrier of one pathogenic variant, each child has a 25% probability of being affected. New mutations are rare.


3. Genetics

The GAA gene is located at 17q25.3, spans 28 kb in total, consists of 20 exons, and encodes a precursor of 952 amino acids. Mature GAA is activated after two-step processing in the lysosome and is targeted from the Golgi apparatus to the lysosome via the mannose-6-phosphate (M6P) receptor. To date, more than 700 pathogenic GAA variants have been reported, and variants classified as pathogenic/likely pathogenic according to ACMG/AMP criteria are listed in the Pompe disease variant database.

The key Western late-onset variant — c.-32-13T>G (IVS1): it weakens the splice acceptor site of exon 2, reducing normal splicing efficiency to about 10~15%. Because a small amount of functional GAA is produced from this residual normal splicing, the patient is CRIM positive (CRIM+). In about 70% of Western LOPD patients, c.-32-13T>G is present on one allele, accompanied by individually diverse variants on the other allele. Homozygosity for this variant is extremely rare.

Frequent variants in East Asia (Korea, China, Japan): the frequency of c.-32-13T>G is lower than in the West, and c.2238G>C (p.Trp746Cys), c.1822C>T (p.Arg608Trp), and others are reported to be relatively frequent in Korean LOPD patients. In the infantile form (IOPD), homozygosity or compound heterozygosity for loss-of-function variants (frameshift, nonsense) predominates. In Taiwan, an exon 18 deletion (IVS17-3C>G) has been identified as a founder variant in a particular ethnic group, but it is known to be rare in Koreans.

Satellite pseudogene (GAA pseudogene): a pseudogene with high sequence similarity to GAA exists near 17q25.3, so in standard PCR-based genetic testing, false positives or co-amplified pseudogene products can confuse interpretation of the results. To avoid this, the use of long-range PCR or gene-specific primers is recommended.

Limitations of phenotype-genotype correlation: even with the same genotype, there is considerable interindividual variation in clinical severity, ERT response, and the rate of decline in respiratory function. Genetic modifiers, environmental factors, and individual differences in the autophagy pathway are presumed to contribute. In particular, with c.-32-13T>G homozygosity, uniform residual GAA activity would theoretically be expected, but clinical severity varies markedly.

Clinically important uses of genetic testing: GAA gene analysis is essential for predicting CRIM status (in IOPD, if both alleles carry loss-of-function variants, the risk of being CRIM negative is high), assessing the risk of inhibitor formation before ERT, family carrier testing, prenatal diagnosis, and confirming positive newborn screening results. Next-generation sequencing (NGS) panels are currently the standard, and copy number variant (CNV) analysis is also performed.


4. General epidemiology

The overall prevalence of Pompe disease is estimated at about 1 in 40,000~57,000 births, but there are considerable differences by clinical subtype and ethnicity. The prevalence of the infantile form (IOPD) is reported as about 1 in 100,000 births and that of the late-onset form (LOPD) as about 1 in 57,000 births, but figures vary with diagnostic criteria and screening methods. There is no difference in frequency by sex, and as an autosomal recessive disorder it affects males and females equally.

Ethnic differences: the prevalence of IOPD is known to be high in African Americans (about 1/14,000), due to the founder effect of the c.2560C>T (p.Arg854Stop) variant. In Taiwan, the prevalence of IOPD is about 1/50,000, higher than in other Asian countries, and the IVS17-3C>G (exon 18 skipping) variant acts as a founder variant in indigenous populations. In China, the proportion of the late-onset form is relatively high. In Korea, the proportion of LOPD is reported to be relatively high compared with the West, and it is not uncommon for patients to be misdiagnosed with adult myopathy or unclassified respiratory failure before belatedly being diagnosed with Pompe disease.

The actual prevalence observed in newborn screening studies tends to be higher than previous clinical estimates. The Taiwanese newborn screening program found decreased GAA enzyme activity in about 1/19,000, the majority of whom were expected to have the LOPD phenotype. US newborn screening also reported a positivity rate of about 1/22,000~1/28,000. Part of this high screening positivity rate is due to mild or false-positive variants (pseudodeficiency alleles, c.1726G>A/c.2065G>A, etc.), and confirmatory genetic testing to distinguish them is essential.

In Korea, newborn screening for Pompe disease was introduced at some regional medical institutions from the mid-2010s, and according to Health Insurance Review & Assessment Service (HIRA) data, the number of patients registered with GSD II is in the dozens, but the actual number of undiagnosed patients is presumed to be greater. Through special copayment reduction (V117) registration, ERT is covered by insurance. Because LOPD patients are often first identified in adult neuromuscular disease clinics, neurology, and pulmonology, improving awareness of Pompe disease within multidisciplinary collaborative systems is important.


5. Pathophysiology

The core pathophysiology of Pompe disease is the inability to break down lysosomal glycogen due to deficiency of lysosomal acid alpha-glucosidase (GAA). Normally, lysosomal GAA breaks down cytoplasmic glycogen particles delivered via autophagosomes and also processes glycogen taken directly into lysosomes. With GAA deficiency, glycogen continuously accumulates within lysosomes, the lysosomes gradually swell, and eventually the lysosomal membrane ruptures, releasing lysosomal enzymes into the cytoplasm and causing cell damage.

Pathophysiology in muscle cells: lysosomal glycogen accumulation is prominent in cardiomyocytes and skeletal muscle fibers (especially type 1 slow-twitch fibers). Lysosomal swelling physically disrupts the myofibril structure and damages the contractile proteins myosin and actin. This process leads to progressive loss of function and death of muscle cells. Lesions are especially prominent in the myocardium and respiratory muscles (diaphragm, intercostal muscles), resulting in hypertrophic cardiomyopathy in the infantile form and respiratory failure in the late-onset form.

Autophagic impairment: in Pompe disease, lysosomal dysfunction goes beyond simple glycogen accumulation to damage the cellular autophagy pathway as a whole. When lysosomes fail to fuse with autophagosomes or the contents of autophagosomes are not degraded, damaged cellular organelles and unfolded proteins accumulate within the cell. This autophagic impairment further worsens muscle fiber damage and is drawing attention as one of the causes of residual muscle lesions that are not fully corrected even by ERT. Treatment strategies combining an autophagy enhancer such as miglustat with ERT target this mechanism.

The M6P receptor targeting pathway and the theoretical basis of ERT: recombinant GAA (rhGAA) administered extracellularly binds to mannose-6-phosphate (M6P) receptors and CI-M6PR (cation-independent M6P receptor) on the cell surface, enters the cell by endocytosis, and is targeted to the lysosome. Because the expression density of M6P receptors is relatively low in muscle cells, the limited efficiency of lysosomal targeting of standard rhGAA within muscle is pointed out as a limitation of the ERT response. The next-generation ERT avalglucosidase alfa improves M6P receptor targeting efficiency by attaching additional M6P residues to the GAA molecule, which is the molecular basis for its clinical effect being superior to existing ERT.

Mechanism of respiratory failure: in LOPD, muscle fiber damage of the diaphragm and accessory respiratory muscles progresses gradually, and inspiratory muscle strength declines. This first appears as hypoventilation during nighttime sleep (nocturnal hypoxemia), and later symptoms appear during the day as well. Decreased FVC (in particular, a greater decrease in FVC in the supine than in the upright position suggests diaphragmatic weakness), decreased MIP (maximal inspiratory pressure), and decreased MEP (maximal expiratory pressure) are physiological indicators of respiratory muscle weakness.


6. Symptoms

The clinical symptoms of Pompe disease differ greatly in age of onset and pattern of major organ involvement depending on residual GAA activity. They are broadly divided into the infantile form (IOPD) and the late-onset form (LOPD).

Symptoms of infantile-onset Pompe disease (IOPD): infants appear normal at birth, but symptoms appear rapidly within 1~6 months of life. The most serious symptom is hypertrophic cardiomyopathy (HCM); echocardiography shows markedly increased ventricular wall thickness, and left ventricular outflow tract obstruction develops, leading to heart failure and arrhythmias. Profound hypotonia produces a 'floppy baby' appearance, with markedly reduced head control and limb movement. Feeding difficulties, poor weight gain, and repeated vomiting are common. Respiratory failure due to respiratory muscle weakness develops, with increased respiratory rate and use of accessory respiratory muscles observed. Macroglossia is present in some cases. Without treatment, most die of cardiopulmonary failure within the first year of life.

Symptoms of the late-onset form (LOPD): the age of onset is widely distributed, from after infancy to several decades of age. The main symptom is progressive proximal limb muscle weakness; in particular, the proximal lower limbs (quadriceps, iliopsoas, gluteal muscles) are affected first, presenting as difficulty climbing stairs, difficulty rising from a chair, and a waddling gait. Prominent weakness of the paraspinal muscles is characteristic, and the resulting lumbar hyperlordosis is a relatively specific finding in LOPD. Respiratory muscle weakness: weakness of the respiratory muscles including the diaphragm causes dyspnea in the supine position (orthopnea), morning headache (nocturnal CO2 retention), and apnea during sleep. Because respiratory symptoms sometimes appear before muscle weakness, Pompe disease should be differentiated in adults presenting with unclassified respiratory failure or sleep-disordered breathing. Dysphagia may appear in advanced LOPD, increasing the risk of aspiration pneumonia. Cardiac involvement is mild or absent in most cases of LOPD.


7. Signs

In the infantile form, the most prominent finding on physical examination is cardiomegaly; a heart murmur may be heard on auscultation, and an enlarged cardiac silhouette is seen on chest X-ray. On ECG, a short PR interval, increased QRS complex voltage, and a left ventricular hypertrophy pattern are characteristic. Profound hypotonia: the limbs hang limp when lifted, and head control in the prone position is almost impossible. Deep tendon reflexes (DTR) are decreased or absent. When macroglossia is present, there is a risk of feeding difficulty and upper airway obstruction. Hepatomegaly may be mild or absent. Creatine kinase (CK) is markedly elevated (5~10 times normal or more), accompanied by elevated aspartate aminotransferase (AST) and lactate dehydrogenase (LDH).

Physical signs of the late-onset form: proximal limb weakness is characteristic. In the chair rise test, arm assistance is needed or rising is impossible. The Gowers sign (rising from the floor by placing the hands on the knees from an all-fours position) is positive. Lumbar hyperlordosis, scapular winging, and inability to walk on tiptoes or heels may be observed. Respiratory function: an FVC in the supine position markedly lower than in the upright position (≥10% difference) strongly suggests diaphragmatic weakness. Hypoxemic episodes are identified on nocturnal oxygen saturation monitoring. CK varies from normal to a 3-fold elevation, and a normal CK does not exclude LOPD.

Neuromuscular function tests: electromyography (EMG) may show a myopathic pattern — short-duration, low-amplitude polyphasic motor unit potentials, increased insertional activity, and residual negative potential discharges — but it is nonspecific. Muscle biopsy (quadriceps or deltoid) characteristically shows vacuolar fibers, PAS-positive material (glycogen accumulation), and an increase in acid phosphatase-positive lysosomes, but may be nonspecific in early or mild cases. Muscle biopsy is not essential in the current era when genetic confirmation is possible, and the standard is to perform enzyme and genetic testing first in suspected patients.


8. Screening

Newborn screening for Pompe disease uses measurement of GAA enzyme activity on dried blood spots (DBS) by fluorometric assay or digital microfluidic technology. This test is technically feasible and cost-effective, and because it offers the clear clinical benefit of preventing cardiomyopathy through early ERT initiation, Pompe disease is being adopted as a recommended newborn screening condition. It is performed in the United States, Taiwan, Japan, Austria, Italy, and some institutions in Korea.

Detailed newborn screening process: ① measurement of GAA enzyme activity on DBS (positive if below the cutoff). ② If the first test is positive, confirmation by repeat DBS testing or measurement of leukocyte GAA activity. ③ GAA gene analysis (confirmation of variants on both alleles). ④ Checking for carriage of pseudodeficiency alleles (c.1726G>A, c.2065G>A, etc.) (variants that lower enzyme activity but do not cause actual disease). ⑤ Assessment of CRIM status (when the infantile form is diagnosed).

Screening for adult LOPD: because LOPD presents in adulthood without being detected by newborn screening, active screening is needed in the following clinical situations. ① Unexplained proximal muscle weakness (especially of the limbs and paraspinal muscles). ② Unexplained respiratory failure or nocturnal hypoventilation. ③ Sleep-disordered breathing (when not adequately corrected even with CPAP). ④ Mild to moderate CK elevation. ⑤ Myopathic pattern on electromyography. In patients with these combinations of symptoms, DBS GAA enzyme activity is measured, and if decreased, confirmatory genetic testing is performed.

Family history-based screening: in families in which a child with Pompe disease was previously born, prenatal diagnosis in the next pregnancy (measurement of enzyme activity or genetic analysis by chorionic villus sampling or amniocentesis), preimplantation genetic testing (PGT), and genetic testing of siblings are possible. Carrier testing of asymptomatic adults is also offered together with genetic counseling.


9. Diagnosis

Pompe disease is confirmed by the combination of GAA enzyme activity measurement and GAA gene analysis. Historically, histological diagnosis by muscle biopsy was used, but noninvasive enzyme and genetic testing is now the standard.

GAA enzyme activity measurement: GAA enzyme activity measurement performed on dried blood spots (DBS) is used as the first-line screening and diagnostic tool. GAA-specific activity is measured using an acidic (pH 3.8~4.0) substrate (4-methylumbelliferyl-α-D-glucoside, 4-MU-αGlu). If GAA activity on DBS is confirmed to be less than 1% of the reference value (severe deficiency) or 1~10% (partial deficiency), confirmatory testing follows. To increase accuracy, a method of selectively measuring only acidic GAA activity after blocking neutral maltase activity with acarbose (the AML test) has been standardized. Measurement of GAA activity in leukocytes or fibroblasts is the confirmatory standard and is more accurate than DBS.

GAA gene analysis: diagnosis is confirmed by identifying pathogenic variants on both alleles. It is important to distinguish pseudodeficiency alleles (c.1726G>A, c.2065G>A) from true pathogenic variants. c.-32-13T>G is a pathogenic variant but retains residual function, so with this variant alone, enzyme activity measurement is performed concurrently before an immediate treatment decision is made.

CRIM status assessment: in patients diagnosed with IOPD, CRIM status is assessed before starting ERT. The presence of GAA protein in the patient's muscle or fibroblasts is confirmed by Western blot, or status is predicted from the type of GAA variant (homozygous/compound heterozygous nonsense+nonsense or nonsense+frameshift → high likelihood of CRIM negativity). The immune response after starting ERT is tracked by measuring anti-GAA IgG antibodies (HSAT, high-sustained antibody titer).

Pulmonary function tests: spirometry (FVC, FEV1, FEV1/FVC), comparison of FVC in the sitting and supine positions (a decrease of ≥10% suggests diaphragmatic weakness), measurement of maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP), nocturnal oxygen saturation monitoring, and polysomnography are essential for assessing respiratory function. In LOPD patients, tracking FVC is the key indicator of treatment response and disease progression.

Motor function assessment: the 6-minute walk test (6MWT), 10-meter walk test, chair rise test (GSGC — Gait, Stairs, Gowers, Chair), and strength measurement (dynamometry) quantify functional status and treatment response. In the infantile form, motor development is assessed with the Denver developmental test, the AIMS (Alberta Infant Motor Scale), and others.


10. Treatment

Enzyme replacement therapy (ERT) is the core of treatment for Pompe disease, and integrated multidisciplinary management, including respiratory support, physical therapy, nutritional management, and immune tolerance induction in CRIM-negative patients, is essential.

First-generation ERT — alglucosidase alfa (Myozyme/Lumizyme): a recombinant human GAA (rhGAA) produced in Chinese hamster ovary (CHO) cells. The standard dose is 20 mg/kg intravenously every other week (q2w). In IOPD, dramatic improvement of cardiomyopathy (reduced ventricular wall thickness, recovery of cardiac function) and prolonged survival after starting ERT have been demonstrated. In LOPD, the LOTS phase 3 clinical trial (van der Ploeg et al., 2010) confirmed a 25.1m improvement in 6-minute walk distance and a 1.2% improvement in FVC compared with placebo, which became the basis for FDA approval. However, because of the limited efficiency of M6P receptor targeting in muscle, gradual decline in motor and respiratory function continues in some patients on long-term treatment.

Second-generation ERT — avalglucosidase alfa (Nexviazyme): a high-mannose-6-phosphate-content rhGAA whose M6P receptor binding affinity is improved about 15-fold over alglucosidase alfa. The standard dose is 40 mg/kg intravenously every other week (q2w). In the COMET phase 3 trial in LOPD, significant superiority over alglucosidase alfa was confirmed in both 6-minute walk distance and respiratory function, leading to FDA and EMA approval in 2021 and Korean approval in 2022. It is currently recommended as first-line treatment in newly diagnosed adult LOPD patients.

Combination of cipaglucosidase alfa + miglustat: cipaglucosidase alfa is another high-M6P rhGAA, and miglustat is a pharmacokinetic enhancer (pharmacological chaperone) that stabilizes the shape of the GAA active site to improve intracellular processing and lysosomal targeting. In the 2023~2024 PROPEL study, improvement in motor and respiratory function was confirmed, and efficacy was recognized in both ERT-naive and ERT-experienced LOPD patients.

CRIM-negative infantile form — immune tolerance induction (ITI): in IOPD patients confirmed as CRIM negative or predicted to have a high-risk genotype, an immune tolerance induction protocol is carried out simultaneously with or before starting ERT. The representative protocol is the combination of methotrexate (MTX) + rituximab + intravenous immunoglobulin (IVIG), and some centers also add cyclophosphamide. Preventing HSAT formation with this protocol greatly improves the ERT response, making prolonged survival and motor development possible even in CRIM-negative IOPD patients.

Respiratory support: when nocturnal hypoventilation is confirmed or FVC is less than 50% of predicted, noninvasive ventilation (NIV: BiPAP or CPAP) is introduced. In advanced respiratory failure, a cough assist device (cough assist, MAC) is used to help clear airway secretions. Tracheostomy and invasive mechanical ventilation are considered at the final stage. Regular assessment of respiratory function and early introduction of NIV reduce pneumonia complications and maintain quality of life.

Physical and rehabilitation therapy and nutrition: resistance exercise and aerobic exercise are reported to enhance the effect of ERT. In patients with dysphagia, modification of diet consistency and swallowing rehabilitation are needed. A high-protein diet may help muscle synthesis, and in IOPD it is important to maintain sufficient protein intake.

Gene therapy: AAV2/8- or AAV9-based GAA gene transfer therapy has shown long-term enzyme expression in animal models, and mRNA-based GAA therapy is also under study. Early results are being reported from phase 1/2 clinical trials, and it is expected to become a therapy that replaces or complements ERT in the future.


11. Prognosis

The prognosis of Pompe disease depends greatly on the form of onset (infantile vs. late-onset), the timing of ERT initiation, CRIM status, and the overall level of multidisciplinary management.

Prognosis of the infantile form (IOPD): in the pre-ERT era, about 89% of untreated IOPD patients died of cardiopulmonary failure within the first year of life. Survival has improved dramatically since the introduction of ERT, but when diagnosed late without newborn screening (when cardiomegaly and muscle damage have already progressed), even if cardiac function improves after starting ERT, motor development is often delayed and long-term ventilator dependence remains. When diagnosed at an asymptomatic stage through newborn screening and ERT is started early: this is far more advantageous for preventing cardiomegaly and normalizing motor development, and normal or near-normal development of motor function has been reported in some patients.

CRIM status and prognosis: when ERT alone is given without ITI to CRIM-negative IOPD patients, high-titer anti-GAA antibodies form in nearly all cases, nullifying ERT. When immune tolerance is maintained through an ITI protocol, a treatment response similar to that of CRIM-positive patients can be obtained even in CRIM-negative patients. Early determination of CRIM status and timely application of ITI are the most important clinical decisions for the prognosis of IOPD.

Prognosis of the late-onset form (LOPD): ERT (alglucosidase alfa or avalglucosidase alfa) can slow disease progression, but cure is not possible. Decline in respiratory function has a greater effect on prognosis than motor function. The higher the pulmonary function (FVC) at the start of treatment, the better the prognosis. Clinical data are accumulating showing that avalglucosidase alfa has a better long-term prognosis than the existing first-generation ERT. Respiratory failure, aspiration pneumonia, and recurrent respiratory infections are the main causes of morbidity and mortality.

Quality of life: because ERT requires hospital visits every other week, there are constraints on daily life and work. Home ERT infusion programs are available in some places. Declining motor function and the use of respiratory support devices impose a psychological burden, and assessment with disease-specific quality of life instruments (PROMIS, Pompe-PROM) is recommended.


12. Prevention

The most effective strategy for preventing Pompe disease is early diagnosis through newborn screening and early initiation of ERT. Especially in the infantile form, starting ERT before cardiomyopathy and muscle damage develop yields markedly better results than treatment after onset. Including Pompe disease in national newborn screening programs is a key health policy for preventing IOPD.

Prophylactic immune tolerance induction for CRIM negativity: when CRIM-negative risk is predicted by genetic analysis in an IOPD neonate, starting an immune tolerance induction (ITI) protocol simultaneously with or before starting ERT is strongly recommended. Prophylactic ITI before HSAT formation has a higher success rate than attempts after HSAT formation.

Genetic counseling and prenatal diagnosis: in families that previously had a child with Pompe disease, early diagnosis by prenatal genetic analysis (CVS or amniocentesis) in the next pregnancy allows preparation to start neonatal ERT immediately after birth. Preventing implantation of an affected embryo through PGT is also an option.

Prevention of respiratory complications in adult LOPD: early onset of respiratory failure is detected through regular pulmonary function tests and nocturnal oxygen saturation monitoring, and when FVC < 50% or nocturnal hypoventilation is confirmed, acute respiratory failure is prevented by early introduction of NIV. Respiratory infections are prevented by keeping pneumococcal and influenza vaccines up to date. In patients with dysphagia, dietary modification and posture training are given concurrently to prevent aspiration pneumonia.

Common prevention guidelines for all patients: preparation of emergency management for ERT infusion adverse effects (infusion-associated reactions, anaphylaxis). Assessment of respiratory function before anesthesia (risk of respiratory failure after extubation with general anesthesia). Consultation with respiratory medicine and anesthesiology before surgery requiring general anesthesia. Carrying a Pompe disease alert card.


13. References

  1. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe disease (LOTS). N Engl J Med. 2010;362(15):1396-1406. DOI: 10.1056/NEJMoa0909859. PMID: 20393176.
  2. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid alpha-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 2007;68(2):99-109. DOI: 10.1212/01.wnl.0000251040.44661.04. PMID: 17210891.
  3. Schoser B, Roberts M, Byrne BJ, et al. Safety and efficacy of avalglucosidase alfa in late-onset Pompe disease (COMET): a randomised, double-blind, active-comparator-controlled, phase 3 trial. Lancet Neurol. 2021;20(12):1012-1026. DOI: 10.1016/S1474-4422(21)00335-X. PMID: 34800381.
  4. Kishnani PS, Goldenberg PC, DeArmey SL, et al. Cross-reactive immunological material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab. 2010;99(1):26-33. DOI: 10.1016/j.ymgme.2009.08.003. PMID: 19800274.
  5. Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics. 2009;124(6):e1116-1125. DOI: 10.1542/peds.2009-0556. PMID: 19948615.
  6. Koeberl DD, Li S, Dai J, et al. mTOR activation with AICAR and rapamycin in combination reduces glycogen content in skeletal muscle of a mouse model of Pompe disease. Mol Genet Metab. 2012;107(4):767-769. DOI: 10.1016/j.ymgme.2012.10.011. PMID: 23142655.
  7. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol. 2013;260(4):951-959. DOI: 10.1007/s00415-012-6636-x. PMID: 22929218.
  8. Hagemans ML, Winkel LP, van Doorn PA, et al. Clinical manifestation and natural course of late-onset Pompe disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671-677. DOI: 10.1093/brain/awh384. PMID: 15689361.
  9. Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012;45(3):319-333. DOI: 10.1002/mus.22329. PMID: 22334375.
  10. Semplicini C, Schoser B. Late-onset glycogenosis type II: an update on clinical, metabolic and genetic aspects. Acta Myol. 2010;29(2):339-343. PMID: 21314019.